The FDA granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adults with relapsed or refractory multiple myeloma (MM) who have been treated with at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.
Belantamab mafodotin is an antibody drug conjugate made up of a humanized anti–B-cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via a